The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities

Abstract

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. The genomic landscape of pediatric ALL has been extensively characterized, allowing for the identification of distinct molecular subtypes of this disease. This in turn has facilitated improvements in risk stratification and tailoring of therapy, resulting in dramatic improvements in survival rates over the past several decades. However, despite these improvements, outcomes remain dismal for the ten percent of patients who continue to fail therapy and relapse. Although the genetic landscape of pediatric ALL is well-understood, increasing evidence suggests that genetic alterations alone are insufficient to promote leukemogenesis and the acquisition of chemoresistance that leads to disease relapse. Instead, cooperating epigenetic alterations are now recognized as important contributors to the aberrant gene expression profiles that are characteristic of the molecular subtypes of ALL, and changes in the epigenetic landscape are now thought to underlie the development of chemoresistance and ultimately disease relapse. This review article focuses on the expanding knowledge of the role of the epigenome in ALL pathogenesis, progression, and response to therapy, and highlights preclinical and clinical efforts to target the epigenome as a means of overcoming chemoresistance and improving outcomes for children with ALL.

Keywords

Acute lymphoblastic leukemia / methylation / histone modification / epigenetic modulator

References

[1] Tasian SK,Hunger SP.Childhood acute lymphoblastic leukemia: integrating genomics into therapy..Cancer2015;121:3577-90 PMCID:PMC4592406

[2] Mullighan CG,Radtke I,Coustan-Smith E.Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia..Nature2007;446:758-64

[3] Liu Y,Shao Y,Wang Z.The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia..Nat Genet2017;49:1211-8 PMCID:PMC5535770

[4] Greaves M.In utero origins of childhood leukaemia..Early Hum Dev2005;81:123-9

[5] Jones PA.The epigenomics of cancer..Cell2007;128:683-92 PMCID:PMC3894624

[6] Bhojwani D.Relapsed childhood acute lymphoblastic leukaemia..Lancet Oncol2013;14:e205-17

[7] Baylin SB.Epigenetic determinants of cancer..Cold Spring Harb Perspect Biol2016;8:a019505 PMCID:PMC5008069

[8] Luo C,Ecker JR.Dynamic DNA methylation: In the right place at the right time..Science2018;361:1336-40 PMCID:PMC6197482

[9] Wong NC,Chatterton Z,Ng HK.A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia..Epigenetics2012;7:535-41

[10] Davidsson J,Andersson A,Heldrup J.The DNA methylome of pediatric acute lymphoblastic leukemia..Hum Mol Genet2009;18:4054-65

[11] Figueroa ME,Andersson AK,Li Y.Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia..J Clin Invest2013;123:3099-111 PMCID:PMC3696550

[12] Almamun M,van Swaay AC,McKay SD.Integrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia..Epigenetics2015;10:882-90 PMCID:PMC4622668

[13] Milani L,Kiialainen A,Flaegstad T.DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia..Blood115:1214-225

[14] Sandoval J,Méndez-González J,Moran S.Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia..Br J Haematol2013;160:406-9 PMCID:PMC3568176

[15] Hogan LE,Yang J,Wong N.Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies..Blood2011;118:5218-26 PMCID:PMC3217405

[16] Kraszewska MD,Larmonie NSD,Sędek Ł.DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL..Leukemia2012;26:367-71

[17] Borssén M,Karrman K,Behrendtz M.Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia..PLoS One2013;8:e65373 PMCID:PMC3675104

[18] Teachey DT.Predicting relapse risk in childhood acute lymphoblastic leukaemia..Br J Haematol2013;162:606-20

[19] Borssén M,Landfors M,Schmiegelow K.DNA methylation adds prognostic value to minimal residual disease status in pediatric T-cell acute lymphoblastic leukemia..Pediatr Blood Cancer2016;63:1185-92

[20] Haider Z,Landfors M,Schmiegelow K.An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression..Cancer Med2019;8:311-24 PMCID:PMC6346238

[21] Audia JE.Histone Modifications and Cancer..Cold Spring Harb Perspect Biol2016;8:a019521 PMCID:PMC4817802

[22] Chi P,Wang GG.Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers..Nat Rev Cancer2010;10:457-69 PMCID:PMC3262678

[23] Blobel GA.CREB-binding protein and p300: molecular integrators of hematopoietic transcription..Blood2000;95:745-55

[24] Mullighan CG,Kasper LH,Payne-Turner D.CREBBP mutations in relapsed acute lymphoblastic leukaemia..Nature2011;471:235-9 PMCID:PMC3076610

[25] Gao J.Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis..Eur Rev Med Pharmacol Sci2018;22:7858-66

[26] Inthal A,Zeginigg M,Grausenburger R.CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia..Leukemia2012;26:1797-803 PMCID:PMC4194312

[27] Gao C,Liu SG,Cui L.Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia..Eur J Haematol2017;99:150-9

[28] Moreno DA,Cortez MAA,Valera ET.Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia..Br J Haematol2010;150:665-73

[29] Sonnemann J,Wittig S,Beck JF.Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents..Br J Haematol2012;158:664-6

[30] Gruhn B,Gruner D,Wittig S.The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia..Leuk Res2013;37:1200-7

[31] Bachmann PS,Janes ME,Davies C.Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition..Blood2010;116:3013-22

[32] Milne TA,Brock HW,Gibbs D.MLL targets SET domain methyltransferase activity to Hox gene promoters..Mol Cell2002;10:1107-17

[33] Okada Y,Lin Y,Li Y.hDOT1L links histone methylation to leukemogenesis..Cell2005;121:167-78

[34] Krivtsov AV,Lemieux ME,Vempati S.H3K79 methylation profiles define murine and human MLL-AF4 leukemias..Cancer Cell2008;14:355-68 PMCID:PMC2591932

[35] Benito JM,Kojima K,Wunderlich M.MLL-rearranged acute lymphoblastic leukemias activate bcl-2 through h3k79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199..Cell Rep2015;13:2715-27 PMCID:PMC4700051

[36] Mar BG,McLean KM,Harris MH.Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia..Nat Commun2014;5:3469 PMCID:PMC4016990

[37] Mar BG,Kahn JD,Koche R.SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia..Blood2017;130:2631-41 PMCID:PMC5731084

[38] Garcia-Manero G,Sanchez-Gonzalez B,Rosner G.Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia..Blood2006;108:3271-9 PMCID:PMC1895437

[39] Schafer E,Negi S,Small D.Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting..Blood2010;115:4798-809 PMCID:PMC2890186

[40] Bernt KM,Sinha AU,Faber J.MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L..Cancer Cell2011;20:66-78 PMCID:PMC3329803

[41] Daigle SR,Therkelsen CA,Jin L.Potent inhibition of DOT1L as treatment of MLL-fusion leukemia..Blood2013;122:1017-25 PMCID:PMC3739029

[42] Gore SD,Sugar E,Miller CB.Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms..Cancer Res2006;66:6361-9

[43] Bhatla T,Morrison DJ,Burke MJ.Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia..Blood2012;119:5201-10 PMCID:PMC3369610

[44] Burke MJ,Pounds S,Ghodke-Puranik Y.A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia..Am J Hematol2014;89:889-95 PMCID:PMC4134715

[45] Vilas-Zornoza A,Abizanda G,Segura V.Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia..Leukemia2012;26:1517-26

[46] Scuto A,Kowolik C,Juhasz A.The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells..Blood2008;111:5093-100 PMCID:PMC2384136

[47] Annesley CE.Novel agents for the treatment of childhood acute leukemia..Ther Adv Hematol2015;6:61-79 PMCID:PMC4365053

[48] Fouladi M,Stewart CF,Schaiquevich P.Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report..J Clin Oncol2010;28:3623-9 PMCID:PMC2917318

[49] Xu Y.Targeting cancer cells with bet bromodomain inhibitors..Cold Spring Harb Perspect Med2017;7:a026674 PMCID:PMC5495050

[50] Sahai V,Collier KA,Munshi HG.Targeting BET bromodomain proteins in solid tumors..Oncotarget2016;7:53997-4009 PMCID:PMC5288238

[51] Zuber J,Wang E,Herrmann H.RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia..Nature2011;478:524-8 PMCID:PMC3328300

[52] Braun T.Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)..Expert Opin Investig Drugs2017;26:803-11

[53] Bardini M,Rizzo F,Savino AM.Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL..Mol Cancer Ther2018;17:1705-16

[54] Da Costa D,Perry T,Petermann E.BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia..Blood Cancer J2013;3:e126 PMCID:PMC3730202

[55] Roberts KG,Payne-Turner D,Yang YL.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia..N Engl J Med2014;371:1005-15 PMCID:PMC4191900

[56] Ott CJ,Bird L,Qi J.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia..Blood2012;120:2843-52 PMCID:PMC3466965

[57] Liu S,Nelson EA,Xiang M.Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2..Mol Cancer Ther2014;13:1194-205 PMCID:PMC4013223